A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
Status:
Recruiting
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacokinetics and pharmacodynamics of STSP-0601 at five dose
levels. The results will help identify the most optimal doses to treat bleedings in
hemophilia patients with inhibitors.